



Supplementary Figure 2. Change in Positive and Negative Syndrome Scale (PANSS) subscale scores and Clinical Global Impressions severity (CGI-S) score from baseline: intention-to-treat set analysis. Mixed-model repeated-measures analysis results showing the change in PANSS sub-scores (positive, negative, and general psychopathology) and CGI-S score for lurasidone 160 mg/day and quetiapine XR 600 mg/day (intention-to-treat set). Results are shown as weekly least squares mean (LS mean)±standard error during 6 weeks of the double-blind trial period. A: PANSS positive subscore. B: PANSS negative subscore. C: PANSS general psychopathology subscore. D: CGI-S score. *p<0.05 vs quetiapine XR. W 1–6, week 1–6.